medigraphic.com
Organo Oficial de la Sociedad Mexicana de Urología

2007, Number 5

<< Back Next >>

Rev Mex Urol 2007; 67 (5)

Urologic applications of botulinic toxin

Vásquez FA, Cortez BR, Velarde CA, Guzmán HF, Morales CJ, Senado LI

Language: Spanish
References: 22
Page: 261-266
PDF size: 1143.14 Kb.


ABSTRACT

The application of the botulinum toxin is a relatively new modality of treatment, initially used for cosmetic intentions, it has become of great utility in other variety of pathologies; it was described with urologic purposes 15 years ago, for the overactivity of the detrusor muscle, nevertheless there are new applications of the toxin describing its benefits for other urologic indications, this article makes a revision of the benefits of this therapy.


REFERENCES

  1. Van Emergem E. Ueber einen neuen anaeroben Bacilus und Seine Beziehungen zum Botulismus. Zeitschrift fur Higiene und Infektionskrankheiten 26:1-56, 1897; traducción reimpresa en Rev Infect Dis. 1979; 1:701-719.

  2. Horowitz BZ. Botulinum Toxin. Crit Care Clin. 2005; 21:825-39.

  3. Shulte-Baukloh H, Weiss C, Stolze T et al. Botuli-num A toxin for the treatment of overactive bladder without detrusor overactivity: urodynamic outcome and patient satisfaction. Urology. 2005;66:82-87.

  4. Ouslander JG. Management of overactive bladder. N Engl J Med. 2004;350:786-99.

  5. Rajkumar GN, Conn IG. Botulinum toxin. A new dimension in the treatment of lower urinary tract dysfunction. Urology. 2004;65:211.

  6. Hirst GR, Watkins AJ, Guerrero K,Wareham K, Emery SJ, Jones DR, Lucas MG. Botulinum toxin B is not an effective treatment of refractory overactive bladder. Urology. 2007;69:69-73.

  7. Karsenty G, Reitz A, Lindemann G, Boy S, Schurch B. Persistence of therapeutic effect after repeated injections of botulinum toxin type A to treat incontinence due to neurogenic detrusor overactivity. Urology. 2006;68:1193-7.

  8. Schulte-Baukloh H, Knispel HH, Stolze T, Weiss C, Michael T, Miller K. Repeated botulinum-A toxin injections in treatment of children with neurogenic detrusor overactivity. Urology. 2005;66:865-70.

  9. Kuo HC. Will suburothelial injection of small dose of botulinum toxin have similar therapeutic effects and less adverse events for refractory detrusor overactivity? Urology. 2006;68:993-8.

  10. Schulte-Baukloh H, Bigalke H, Heine G, Pape D, Stuerzebecher B, Miller K, Knispel HH. Antibodies against botulinum neurotoxin type A as a cause of treatment failure after the first detrusor injection. Urology. 2007;69:575.

  11. Khera M, Somogyi GT, Salas NA, Kiss S, Boone TB, Smith CP. In vivo effects of botulinum toxin-A on visceral sensory function in chronic spinal cord-injured rats. Urology. 2005;66:208-12.

  12. Kuo HC. Prostate botulinum a toxin injection an alternative treatment for benign prostatic obstruction in poor surgical candidates. Urology. 2005;65: 670-4.

  13. Zalvan C, Bentsianov B, Gonzalez-Yanes O, Blitzer A. Noncosmetic uses of botulinum toxin. Dermatol Clin. 2004;22:187-95.

  14. Munchau A, Bhatia KB. Uses of botulinum toxin injection in medicine today. BMJ. 2000;320:161-5.

  15. Chancellor M. Treatment of interstitial cystitis. Urology. 2004;63:84-92.

  16. Sangeeta T. Botulinum toxin: Form life-threatening disease to novel medical therapy. Am J Obstet. 2007; 196:7-15.

  17. Mandell, Benett, Dolin. Principles and practice of infectious diseases. 6th edition, Churchill-Livingstone; chapter 243, 2005.

  18. Cohen, Powderly. Infectious diseases, 2nd edition, Mosby, 2004.

  19. Walsh. Campbell’s Urology, 8th edition, McGraw-Hill, 2004.

  20. Moore C, Rackley R, Goldman H. Urologic applications of botox: Curr Urol Rep. 2005;6(6):419-23.

  21. Hallet M. One man’s poison-Clinical applications of Botulinum toxin. N Engl J Med. 1999;341:118-20.

  22. Karsenty G, Reitz A, Wefer B, Boy S, Schurch B. Understanding Detrusor sphincter dyssynergia significance of chronology. Urology. 2005;66:763-8.




2020     |     www.medigraphic.com